Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: haemophilia therapeutics - Ascension Healthcare/PolyTherics

Next Previous
Drug Profile

Research programme: haemophilia therapeutics - Ascension Healthcare/PolyTherics

Alternative Names: ChapAte; Haemophilia therapeutics - Ascension Healthcare; Haemophilia therapeutics - Celtic Pharma/PolyTherics; Long-acting blood coagulation factor IX - Ascension Healthcare; Long-acting blood coagulation factor VIIa -Ascension Healthcare; Long-acting blood coagulation factor VIII -Ascension Healthcare; PBB 8 CH; PBB 8 SQ; Protein therapeutics - Celtic Pharma/Polytherics; SubcutAte; TheraPEG™ Factor IX; TheraPEG™ Factor VIIa; TheraPEG™ Factor VIII

Latest Information Update: 28 Jan 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celtic Pharma; PolyTherics
  • Developer Ascension Healthcare; PolyTherics
  • Class Blood coagulation factors; Polyethylene glycols
  • Mechanism of Action Blood coagulation factor replacements; Factor IX stimulants; Factor VIII replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Haemophilia A; Haemophilia B

Most Recent Events

  • 28 Jan 2021 No recent reports of development identified for preclinical development in Haemophilia-A in United Kingdom (SC, Injection)
  • 23 Jan 2019 Preclinical development is ongoing in United Kingdom (SC, Injection) (Ascension Healthcare pipeline, January 2019)
  • 04 Jan 2019 Ascension Healthcare plans a phase II trials of SubcutAte and ChapAte programmes for Haemophilia A in 2019 (Ascension Healthcare pipeline, January 2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top